Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what evidence NICE has identified as the basis for its clinical assessment of puberty blockers for gender dysphoria; and whether NICE has undertaken (a) scoping and (b) evaluation exercises since 2015.

The National Institute for Health and Care Excellence (NICE) has not developed guidance on, or made a clinical assessment of, puberty blockers for gender dysphoria. In 2020, NICE developed two evidence summaries:

• Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria; and
• Gender-affirming hormones for children and adolescents with gender dysphoria.

These summaries were commissioned by NHS England and developed by NICE to an NHS England process. They helped inform the Cass review.